S. Surget

发表

Uncovering the role of p53 splice variants in human malignancy: a clinical perspective

J. Bourdon, M. Khoury, S. Surget, 2013, OncoTargets and therapy.

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

R. Bataille, G. Descamps, M. Amiot, 2012, Cancer research.

A Functional, New Short Isoform of Death Receptor 4 in Ewing's Sarcoma Cell Lines May be Involved in TRAIL Sensitivity/Resistance Mechanisms

C. Pellat-deceunynck, F. Tirode, S. Surget, 2012, Molecular Cancer Research.

Mcl‐1128–350 fragment induces apoptosis through direct interaction with Bax

M. Amiot, C. Pellat-deceunynck, S. Surget, 2010, FEBS letters.

Tumor and Stem Cell Biology Cell Death via DR 5 , but not DR 4 , Is Regulated by p 53 in Myeloma Cells

R. Bataille, G. Descamps, M. Amiot, 2012 .

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

G. Descamps, M. Amiot, C. Pellat-deceunynck, 2014, Leukemia and Lymphoma.

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway

G. Descamps, M. Amiot, C. Pellat-deceunynck, 2014, BMC Cancer.

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.

M. Chapman, J. Keats, P. Lehner, 2022, Blood.

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

R. Bataille, M. Amiot, S. Surget, 2012, British journal of haematology.

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

R. Bataille, G. Descamps, M. Amiot, 2013, Blood Cancer Journal.